Abstracts tagged "Biomarkers"

Abstract Number: 0747 • ACR Convergence 2020
Isotope-Labeling-LC-MS-based Metabolic Profiling of Multiple Serum Sample Sets for the Discovery of High-confidence Rheumatoid Arthritis Biomarkers
Xiaohang Wang¹, Wei Han¹, Liang Li¹, Stephanie Wichuk², Edna Hutchings³, Rana Dadashova³, Joel Paschke³ and Walter Maksymowych², ¹Department of Chemistry, University of Alberta, Edmonton, AB, Canada, ²University of Alberta, Edmonton, AB, Canada, ³CARE Arthritis, Edmonton, AB, Canada
Background/Purpose: Early diagnosis of rheumatoid arthritis (RA) is hampered by suboptimal accuracy of currently available serological biomarkers. In this work, we applied a high-performance chemical…
Abstract Number: 1061 • ACR Convergence 2020
Daily Myositis Symptom Changes Collected via a Smartphone-Based App Are Associated with Flare Occurrence – Providing Evidence of Potential Digital Biomarkers
Alexander Oldroyd¹, Belay Yimer², Max Little³, William Dixon² and Hector Chinoy⁴, ¹University of Manchester, Manchester, United Kingdom, ²Centre for Epidemiology Versus Arthritis, University of Manchester, Manchester, United Kingdom, ³University of Birmingham, Birmingham, United Kingdom, ⁴The University of Manchester, Manchester, United Kingdom
Background/Purpose: The concept of idiopathic inflammatory myopathy (IIM) flare is widely used, although no consensus definition exists. Studies have demonstrated the feasibility and utility of…
Abstract Number: 1204 • ACR Convergence 2020
Use of Multi-Biomarker Disease Activity Scores to Assess Biosimilarity in a Phase 3 Randomized Controlled Trial Comparing Biosimilar Infliximab-qbtx (PF‑06438179/GP1111) with EU-Sourced Reference Infliximab in Patients with Active RA
Jonathan Kay¹, Daniel Alvarez², Muhammad Iftikharur Rehman³, Min Zhang⁴ and Noriko Iikuni⁵, ¹University of Massachusetts Medical School, Worcester, MA, ²Pfizer, Collegeville, PA, ³Pfizer, Andover, MA, ⁴Pfizer, La Jolla, CA, ⁵Pfizer, New York, NY
Background/Purpose: The multi-biomarker disease activity (MBDA; Vectra® DA, Myriad Genetics, Inc.) score is calculated from concentrations of 12 serum proteins to assess disease activity (DA)…
Abstract Number: 1510 • ACR Convergence 2020
Platelet-bound C4d Is Associated with Platelet Activation and Arterial Thrombotic Events
Yevgeniya Gartshteyn¹, Adam Mor², Daichi Shimbo², Leila Khalili³, Teja Kapoor⁴, Laura Geraldino-Pardilla⁵, Roberta Vezza Alexander⁶, Thierry Dervieux⁷ and Anca Askanase², ¹Columbia University College of Physicians and Surgeons, Glen Rock, NJ, ²Columbia University College of Physicians and Surgeons, New York, NY, ³Columbia University Medical Center, New Haven, CT, ⁴Columbia University College of Physicians and Surgeons, Leonia, NJ, ⁵Division of Rheumatology, Columbia University Vagelos College of Physicians and Surgeons, New York, ⁶Exagen Inc, Vista, CA, ⁷Prometheus Biosciences Inc, Irvine, CA
Background/Purpose: Platelets have a well-defined role in arterial thrombosis, and platelet-bound complement activation products (PC4d) correlate with vascular thromboses in patients with Systemic Lupus Erythematosus…
Abstract Number: 1792 • ACR Convergence 2020
Platelet-bound C4d Is Associated with an Increased Risk of Arterial and Venous Thromboses in SLE
Yevgeniya Gartshteyn¹, Roberta Vezza Alexander², John Conklin³, Thierry Dervieux⁴ and Anca Askanase⁵, ¹Columbia University College of Physicians and Surgeons, Glen Rock, NJ, ²Exagen Inc, Vista, CA, ³Exagen Inc., Vista, CA, ⁴Prometheus Biosciences Inc, San Diego, CA, ⁵Columbia University College of Physicians and Surgeons, New York, NY
Background/Purpose: Platelet-bound complement activation products (PC4d), defined as PC4d20 net mean fluorescent intensity [MFI], or a thrombotic risk score that includes PC4d, C3 and anti-phosphatidylserine/prothrombin…
Abstract Number: 1922 • ACR Convergence 2020
Association of Leukocyte Populations in Peripheral Blood and Arterial Wall Inflammation Assessed by FDG-PET in Takayasu’s Arteritis and Giant Cell Arteritis
K. Bates Gribbons¹, Kaitlin Quinn², Mark Ahlman³, Peter Merkel⁴ and Peter C. Grayson⁵, ¹McGovern Medical School UT Houston, Houston, TX, ²Systemic Autoimmunity Branch, National Institutes of Health, NIAMS, Bethesda, ³National Institutes of Health, Clinical Center, Radiology and Imaging Sciences, Bethesda, MD, ⁴University of Pennsylvania, Philadelphia, PA, ⁵Systemic Autoimmunity Branch, National Institutes of Health, NIAMS, Bethesda, MD
Background/Purpose: Positron emission tomography (PET) is useful to demonstrate fluorodeoxyglucose (FDG) uptake in the large arteries in both Takayasu’s arteritis (TAK) and giant cell arteritis…
Abstract Number: 0424 • ACR Convergence 2020
Anti-Collagen II Antibodies in Patients with Relapsing Polychondritis
Kristina Wells¹, Marcela Ferrada², Emily Rose², Keith Sikora³, Wendy Goodspeed², Kaitlin Quinn⁴ and Peter C. Grayson⁵, ¹Systemic Autoimmunity Branch, Vasculitis Translational Research Program, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, ²Systemic Autoimmunity Branch, Vasculitis Translational Research Program, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, ³National Institutes of Health Clinical Center, Bethesda, MD, ⁴Systemic Autoimmunity Branch, National Institutes of Health, NIAMS, Washington, DC, ⁵Systemic Autoimmunity Branch, National Institutes of Health, NIAMS, Bethesda, MD
Background/Purpose: Relapsing polychondritis (RP) is a highly heterogenous systemic inflammatory disorder that affects many organ systems, in particular, cartilaginous structures. Clinical presentations in RP are…
Abstract Number: 0756 • ACR Convergence 2020
Increased Risk of Hospitalization in Patients with RA Who Are ACPA Positive and Shared Epitope Positive
Joe Zhuo¹, Manasi Suryavanshi¹, Lawshia Priya², Vadim Khaychuk¹, John Vaile¹, Jing Cui³, Nancy Shadick⁴ and Michael Weinblatt³, ¹Bristol-Myers Squibb Company, Princeton, NJ, ²Mu-Sigma, Bangalore, India, ³Brigham and Women's Hospital, Boston, MA, ⁴Division of Rheumatology, Inflammation, and Immunity; Brigham and Women’s Hospital and Harvard Medical School, Boston, MA
Background/Purpose: A strong genetic association between HLA-DRB1 alleles containing the shared epitope (SE) and RA has been described.1 The SE has been associated with ACPA…
Abstract Number: 1106 • ACR Convergence 2020
MMP Mediated Type I Collagen Degradation Is Associated with Erosive Hand Osteoarthritis in a Hospital-based Observational Cohort – the NOR-HAND Study
Christian Thudium¹, Neha Sharma², Marthe Gløersen³, Peder Frederiksen², Anne C. Bay-Jensen¹ and Ida Haugen³, ¹Nordic Bioscience, Herlev, Denmark, ²Nordic Bioscience, Herlev, ³Diakonhjemmet Hospital, Oslo, Norway
Background/Purpose: Hand osteoarthritis (OA) is a common degenerative joint disease affecting mainly the interphalangeal and first carpometacarpal joints. The disease manifests as inflammation and deterioration…
Abstract Number: 1213 • ACR Convergence 2020
Discrepancy Between the Multi-biomarker Disease Activity Score and Clinical Disease Activity Scores in a 2‑Part, Multicenter Study of Repository Corticotropin Injection (Acthar® Gel) for Patients with Persistently Active Rheumatoid Arthritis
Roy Fleischmann¹, Jingyu Liu², Julie Zhu², Oscar Segurado³ and Daniel Furst*⁴, ¹Southwestern Medical Center, Metroplex Clinical Research Center, Dallas, TX, ²Mallinckrodt Pharmaceuticals, Bedminster, NJ, ³SSI Strategy, San Jose, CA, ⁴Department of Medicine, Division of Rheumatology, University of California at Los Angeles, Los Angeles, California, USA, Los Angeles, CA
Background/Purpose: Assessment of disease activity in RA with validated measures, such as the Disease Activity Score with 28 joint count and erythrocyte sedimentation rate (DAS28-ESR)…
Abstract Number: 1512 • ACR Convergence 2020
Trajectory Analysis of Repeat Renal Biopsies Identified Previous Endocapillary Proliferation as Predictor of Damage and End Stage Renal Disease in Pure Membranous Lupus Nephritis
Andrea Fava¹, Avi Rosenberg², Serena Bagnasco², Paride Fenaroli², Jessica Li¹, Jose Monroy-Trujillo², Derek Fine² and Michelle Petri³, ¹Johns Hopkins University, Baltimore, MD, ²Johns Hopkins University, Baltimore, ³Johns Hopkins University School of Medicine, Baltimore
Background/Purpose: . Pure membranous (class V) lupus nephritis is considered a less aggressive phenotype, but renal fibrosis and chronic kidney disease may develop. Whether this…
Abstract Number: 1796 • ACR Convergence 2020
A Panel of Urinary Proteins Predicts Active Lupus Nephritis and Response to Rituximab Treatment
Jennifer Davies¹, Emil Carlsson¹, Angela Midgley¹, Eve Smith¹, Ian Bruce², Michael Beresford¹ and Christian Hedrich³, ¹Department of Women's and Children's Health, Institute of Life Course and Medical Sciences, Liverpool, England, United Kingdom, ²Centre for Epidemiology Versus Arthritis, The University of Manchester and NIHR Manchester Biomedical Research Centre, Manchester University Hospitals NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, United Kingdom, ³University of Liverpool, Liverpool, United Kingdom
Background/Purpose: Approximately 30% of patients with adult-onset systemic lupus erythematosus (SLE) develop lupus nephritis (LN). Presence and/or severity of LN are currently assessed by renal…
Abstract Number: 1933 • ACR Convergence 2020
Small Vessel Vasculitis Surrounding a Preserved Temporal Artery: Search for Tissue Biomarkers with Potential Diagnostic Value
Georgina Espígol-Frigolé¹, Roser Alba-Rovira², Salvador Naranjo-Suárez³, Magda Terenas⁴, Sergio Prieto-González¹, Marc Corbera-Bellalta³, Javier Marco-Hernández⁴, Marco A. Alba¹, Farah Kamberovic³, Roberto Ríos-Garcés¹, Jose Hernández-Rodríguez¹ and Maria C. Cid¹, ¹Vasculitis Research Unit, Department of Systemic Autoimmune Diseases, Hospital Clínic de Barcelona, IDIBAPS, University of Barcelona, Barcelona, Spain., Barcelona, Catalonia, Spain, ²Vasculitis Research Unit, Department of Autoimmune Diseases, Hospital Clínic, University of Barcelona, IRB-CELLEX. Institut d’Investigacions Biomèdiques August Pi Sunyer (IDIBAPS), Barcelona, Spain, Barcelona, ³IDIBAPS, Barcelona, Spain, ⁴Hospital Clinic Barcelona, Barcelona, Spain
Background/Purpose: Systemic vasculitides are complex and heterogeneous diseases with overlapping features that frequently pose a diagnostic challenge to clinicians. The temporal artery biopsy (TAB) is…
Abstract Number: 014 • 2020 Pediatric Rheumatology Symposium
Successful Validation of a Rapid Point-of-care Test for Serum Calprotectin (MRP8/14) as Biomarker in Juvenile Idiopathic Arthritis
Dirk Foell¹, Carolin Park ², Linda Ziegler ², Dirk Holziner ³, Kirsten Minden ⁴, Renato Cotti ⁵ and Jakob Weber ⁵, ¹University Hospital Muenster, Muenster, Nordrhein-Westfalen, Germany, ²University of Muenster, Muenster, Germany, ³University of Essen, Essen, Germany, ⁴Berlin, Germany, ⁵Buehlmann Laboratories, Schoenenbuch, Switzerland
Background/Purpose: Treat-to-target strategies are established for the therapeutic approach to patients suffering from juvenile idiopathic arthritis (JIA). Another proposed therapeutic concept in pediatric rheumatology involves…
Abstract Number: 022 • 2020 Pediatric Rheumatology Symposium
Association of Plasma Metabolomic Profiles with Methotrexate Response in Juvenile Idiopathic Arthritis
Ryan Funk¹ and Mara Becker ², ¹University of Kansas, Leawood, Kansas, ²Duke University Medical Center/Duke Clinical Research Institute, Chapel Hill
Background/Purpose: Despite efforts to identify biomarkers to guide therapy in the treatment of juvenile idiopathic arthritis (JIA), drug therapy remains a trial-and-error process. In the…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].